Analysts Set Sanofi (NASDAQ:SNY) PT at $60.00

Sanofi (NASDAQ:SNY) has been assigned an average recommendation of “Buy” from the five analysts that are currently covering the stock, Marketbeat Ratings reports. Two research analysts have rated the stock with a hold rating, one has assigned a buy rating and two have given a strong buy rating to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $62.50.

A number of analysts have recently weighed in on SNY shares. Sanford C. Bernstein raised Sanofi to a “strong-buy” rating in a research note on Thursday, January 30th. Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a “sell” rating to a “hold” rating in a research note on Thursday, January 30th. StockNews.com downgraded Sanofi from a “buy” rating to a “hold” rating in a report on Thursday, December 12th. Finally, The Goldman Sachs Group initiated coverage on Sanofi in a research note on Friday, March 21st. They issued a “neutral” rating and a $65.00 target price for the company.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Abel Hall LLC increased its holdings in shares of Sanofi by 1.8% during the fourth quarter. Abel Hall LLC now owns 10,990 shares of the company’s stock valued at $530,000 after acquiring an additional 194 shares in the last quarter. Providence Capital Advisors LLC raised its stake in shares of Sanofi by 0.4% in the fourth quarter. Providence Capital Advisors LLC now owns 55,001 shares of the company’s stock worth $2,653,000 after purchasing an additional 201 shares during the last quarter. Keudell Morrison Wealth Management lifted its holdings in shares of Sanofi by 1.7% during the fourth quarter. Keudell Morrison Wealth Management now owns 12,928 shares of the company’s stock valued at $624,000 after purchasing an additional 217 shares in the last quarter. Bailard Inc. increased its holdings in Sanofi by 1.4% in the 4th quarter. Bailard Inc. now owns 16,359 shares of the company’s stock worth $789,000 after buying an additional 220 shares in the last quarter. Finally, Old Port Advisors raised its position in Sanofi by 0.6% in the 4th quarter. Old Port Advisors now owns 36,704 shares of the company’s stock worth $1,770,000 after buying an additional 232 shares during the last quarter. Institutional investors own 14.04% of the company’s stock.

Sanofi Trading Down 0.9 %

NASDAQ SNY opened at $55.45 on Friday. The stock’s 50-day simple moving average is $54.84 and its two-hundred day simple moving average is $52.82. Sanofi has a twelve month low of $45.22 and a twelve month high of $60.12. The company has a quick ratio of 1.14, a current ratio of 1.46 and a debt-to-equity ratio of 0.15. The company has a market capitalization of $140.72 billion, a price-to-earnings ratio of 22.27, a PEG ratio of 1.01 and a beta of 0.58.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings results on Thursday, January 30th. The company reported $0.70 EPS for the quarter, meeting analysts’ consensus estimates of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. Research analysts forecast that Sanofi will post 4.36 EPS for the current fiscal year.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.